Company profile
Alector, Inc.
NASDAQ: ALEC · Healthcare · Biotechnology
#538 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
41DFH 34DQ 61GM 14SS 56
v0.1 · 65/100 weight · provisional
↑ filing timeliness, market scale · ↓ return on equity, revenue growth (YoY)
Methodology →Revenue TTM
$18.4M
Rev growth YoY (TTM)
-79.2%
Net income (FY)
-$142.9M
Employees
103
as of 2026-08-13
Market cap
$238.7M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$21.0M$21.0M2025
Net income-$142.9M-$142.9M2025
Operating income-$156.0M-$156.0M2025
Total assets$293.2M$293.2M2025
Liabilities$262.6M$262.6M2025
Equity$30.6M$30.6M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2021
By product
Phase Three License100%
By geography
Not disclosed.
The read
What is Alector, Inc.’s revenue?
Alector, Inc. booked $21.0M in FY2025 revenue, contracting 79% year over year — slower than 88% of Healthcare companies we track, at a -679.2% net margin.
Peers · Healthcare
Ayurcann Holdings Corp.57CItem 9 Labs Corp.——SQZ Biotechnologies Company——MaxCyte, Inc.48DSCYNEXIS, Inc.60CEvofem Biosciences, Inc.42DNeighbors
San Mateo →Key facts
CEOArnon Rosenthal
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: ALEC
Employees103
IPO date2019-02-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.